Seer, Inc. (SEER)
| Market Cap | 137.02M |
| Revenue (ttm) | 15.67M |
| Net Income (ttm) | -83.00M |
| Shares Out | 64.94M |
| EPS (ttm) | -1.30 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 339,960 |
| Open | 2.130 |
| Previous Close | 2.120 |
| Day's Range | 2.070 - 2.138 |
| 52-Week Range | 1.455 - 5.650 |
| Beta | 1.52 |
| Analysts | Hold |
| Price Target | 7.00 (+231.75%) |
| Earnings Date | May 8, 2024 |
About SEER
Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratori... [Read more]
Financial Performance
In 2023, Seer, Inc.'s revenue was $16.66 million, an increase of 7.54% compared to the previous year's $15.49 million. Losses were -$86.28 million, -7.20% less than in 2022.
Financial StatementsAnalyst Forecast
According to one analyst, the rating for SEER stock is "Hold" and the 12-month stock price forecast is $7.0.
News
Seer Reports First Quarter 2024 Financial Results
Demonstrated the power of the Proteograph Product Suite with a growing number of customer presentations and publications Demonstrated the power of the Proteograph Product Suite with a growing number o...
Seer Launches New Technology Access Center in Europe to Expand Accessibility to Unbiased Proteomic Solutions
New Seer Technology Access Center to open in Bonn, Germany Provides life sciences researchers conducting proteomic studies full-service access to the Seer Proteograph™ Product Suite and mass spectrome...
Seer to Report First Quarter 2024 Financial Results on May 8, 2024
REDWOOD CITY, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wi...
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data Enhanced access to the Proteograph Product Suite and demonstrated its power with new customer data
Seer to Participate in the TD Cowen 44th Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...
Seer Proteograph™ Enables Unprecedented Genetic Marker Mapping for Proteogenomics Studies to Advance Drug and Biomarker Discovery
Study led by Weill Cornell Medicine demonstrates identification of protein altering variants for population-scale protein quantitative trait loci (pQTL) studies
Seer to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wil...
Seer to Present at the J.P. Morgan 42nd Annual Health Care Conference
REDWOOD CITY, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...
Seer to Present at the Canaccord MedTech, Diagnostics and Digital Health & Services Forum
REDWOOD CITY, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced company man...
Seer Wins Proteomics Solution of the Year by BioTech Breakthrough and Named #5 on Deloitte Technology Fast 500
Seer technology receives recognition for excellence in the field of proteomics Seer technology receives recognition for excellence in the field of proteomics
Seer Reports Third Quarter 2023 Financial Results
Expanded access to the Proteograph™ Product Suite through the Seer Technology Access Center, new distributors and a new Center of Excellence Expanded access to the Proteograph™ Product Suite through t...
Seer Announces Addition of Panome Bio to Centers of Excellence (COE) Program
Panome Bio adds deep, unbiased proteomics to their proprietary metabolomics platform to deliver innovative multi-omics services Panome Bio adds deep, unbiased proteomics to their proprietary metabolom...
Seer to Report Third Quarter 2023 Financial Results on November 7, 2023
REDWOOD CITY, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report...
Seer to Participate in Upcoming September Investor Conferences
REDWOOD CITY, Calif., Sept. 08, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced company management...
Seer Reports Second Quarter 2023 Financial Results
Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies Launched Proteograph XT Assay Kit, enabling rapid proteomics and large-scale studies
Seer to Present at the Canaccord Genuity 43rd Annual Growth Conference
REDWOOD CITY, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that the co...
Seer to Report Second Quarter 2023 Financial Results on August 8, 2023
REDWOOD CITY, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, today announced that it wil...
Seer Collaborates to Make Scalable, Unbiased Proteomics Accessible to More Researchers via new Seer Technology Access Center
Expanded collaboration with Thermo Fisher Scientific combines the new Seer Proteograph™ XT Assay Kit with the new Thermo Scientific™ Orbitrap™ Astral™ Mass Spectrometer to empower the scientific commu...
Seer Launches the Proteograph XT Assay Kit: Allowing Labs to Easily Expand Their View of the Proteome and Scale Their Studies
Seer's Proteograph XT pushes the boundaries of biological discovery by enabling rapid proteomics across a range of sample types and species with unprecedented resolution and scale Seer's Proteograph X...
Seer Reports First Quarter 2023 Financial Results
Grew revenue 22% year-over-year with continued growth in installed base and an increasing number of customer presentations and publications REDWOOD CITY, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Seer,...
Seer to Report First Quarter 2023 Financial Results on May 9, 2023
REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will repor...
Seer's Proteograph™ Product Suite identifies undiscovered links between protein variants and lung cancer progression
Peptide-level insights from deep, unbiased proteomics enable protein variant analysis of patient samples, revealing potential non-small cell lung cancer biomarkers Peptide-level insights from deep, un...
Seer Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Full Year 2023 Outlook
Grew revenue 134% and increased instruments shipped 129% year over year Grew revenue 134% and increased instruments shipped 129% year over year
Seer to Present at the Cowen 43rd Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that the company wi...
Seer to Report Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced that it will report...